Teng Bo, Xin Ding, Wen Lianji, Cui Shuxun, Jin Chunshun
Department of Otolaryngology, Second Hospital of Jilin University,Changchun 130041, China.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2007 Jun;21(12):552-4.
To explore the possibility of 10-23DNAzyme becoming a new gene therapy for laryngeal carcinoma treatment at the cell level.
Thiosthorothioate 10-23DNAzyme specific to eIF4E gene mRNA 1059 was designed and synthesized, and its inhibition effects on the expression of eIF4E gene in Hep-2 cells were observed.
The expression of eIF4E gene was remarkable depressed after Hep-2 cells was transfected by DNAzyme. The level of inhibiting eIF4E in hep-2 cells transfected by DNAzyme was lower than that by only lipofectamine 2000 transfected and Hep-2.
The expression of eIF4E gene in Hep-2 cells 10-23DNAzyme can be highly blocked. It is a specific and effective gene therapeutic means.
在细胞水平上探讨10-23脱氧核酶成为喉癌治疗新的基因治疗方法的可能性。
设计并合成针对eIF4E基因mRNA 1059的硫代磷酸酯10-23脱氧核酶，观察其对Hep-2细胞中eIF4E基因表达的抑制作用。
脱氧核酶转染Hep-2细胞后，eIF4E基因的表达明显受到抑制。脱氧核酶转染的Hep-2细胞中eIF4E的抑制水平低于仅用脂质体2000转染的Hep-2细胞。
10-23脱氧核酶可高度阻断Hep-2细胞中eIF4E基因的表达。它是一种特异性和有效的基因治疗手段。
